A Phase I/II, Multi-Center, Open-Label, Dose-Escalation, Safety and Efficacy Study of PHY906 Plus Capecitabine in Patients With Advanced Pancreatic Carcinoma

NCT00411762 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Cancer

Interventions

DRUG: Capecitabine
DRUG: PHY906

Sponsor

Yale University

Collaborators

[object Object]
[object Object]
[object Object]